Novartis meningitis B vaccine Bexsero® receives FDA Breakthrough Therapy designation in the US

The designation highlights the potential of Bexsero to meet the urgent need for a licensed vaccine in the US against unpredictable and devastating meningitis B Bexsero, already approved in Europe, Canada and Australia, is the only broad coverage meningitis B vaccine that can be used from two months of age Bexsero was recently provided to two US universities under an …

#wvcusa recent advances for Meningococcal vaccine by Dr Peter Dull @Novartis Vaccines

  Meningococcal vaccine: Dr Peter Dull, Head Development Meningococcal Vaccines at Novartis Vaccines and Diagnostics delivered an interested presentation last week at the World Vaccine Congress about the recent advances on Meningococcal vaccine. Some Key points raised in the presentation: Dr Dull  mentioned that the company goal was to design a broadly protective Meningococcal B vaccine. The capsule of Men …